Imaging biomarkers in prostate cancer: role of PET/CT and MRI

Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after treatment, but it is not able to provide a clear distinction between locoregional and distant disease. Molecular and functional...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2015-04, Vol.42 (4), p.644-655
Main Authors: Picchio, M., Mapelli, P., Panebianco, V., Castellucci, P., Incerti, E., Briganti, A., Gandaglia, G., Kirienko, M., Barchetti, F., Nanni, C., Montorsi, F., Gianolli, L., Fanti, S.
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnosis
Adenocarcinoma - diagnostic imaging
Animals
Biomarkers
Cardiology
Humans
Imaging
Magnetic Resonance Imaging
Male
Medicine
Medicine & Public Health
Multimodal Imaging
Nuclear Medicine
Oncology
Orthopedics
Positron-Emission Tomography
Prostate cancer
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms - diagnosis
Prostatic Neoplasms - diagnostic imaging
Radiology
Radiopharmaceuticals - pharmacokinetics
Review Article
Tomography
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Prostate-specific antigen (PSA) is currently the most widely used biomarker of prostate cancer (PCa). PSA suggests the presence of primary tumour and disease relapse after treatment, but it is not able to provide a clear distinction between locoregional and distant disease. Molecular and functional imaging, that are able to provide a detailed and comprehensive overview of PCa extension, are more reliable tools for primary tumour detection and disease extension assessment both in staging and restaging. In the present review we evaluate the role of PET/CT and MRI in the diagnosis, staging and restaging of PCa, and the use of these imaging modalities in prognosis, treatment planning and response assessment. Innovative imaging strategies including new radiotracers and hybrid scanners such as PET/MRI are also discussed.
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-014-2982-5